Verona Pharma Q3 2023 Earnings Report $66.47 +2.28 (+3.55%) As of 01:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Verona Pharma EPS ResultsActual EPS-$0.18Consensus EPS -$0.27Beat/MissBeat by +$0.09One Year Ago EPSN/AVerona Pharma Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AVerona Pharma Announcement DetailsQuarterQ3 2023Date11/2/2023TimeN/AVRNA Upcoming EarningsVerona Pharma will be holding an earnings conference call on Thursday, February 27 at 9:00 AM Eastern. Interested parties can register for or listen to the call. Conference Call ResourcesPress ReleaseVRNA Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Verona Pharma Earnings HeadlinesVerona Pharma Announces March 2025 Investor Conference ParticipationFebruary 18 at 6:00 AM | globenewswire.comVerona Pharma (NASDAQ:VRNA) Given New $72.00 Price Target at Canaccord Genuity GroupFebruary 15, 2025 | americanbankingnews.com70%, 80%, 90% Win Rates? Grab Your Free Cheatsheets Today!Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets.February 21, 2025 | WealthPress (Ad)Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate UpdateFebruary 13, 2025 | globenewswire.comVerona Pharma (NASDAQ:VRNA) Reaches New 12-Month High After Analyst UpgradeFebruary 13, 2025 | americanbankingnews.comPiper Sandler Sticks to Their Buy Rating for Verona Pharma (VRNA)February 5, 2025 | markets.businessinsider.comSee More Verona Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Verona Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Verona Pharma and other key companies, straight to your email. Email Address About Verona PharmaVerona Pharma (NASDAQ:VRNA), a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. The company was incorporated in 2005 and is headquartered in London, the United Kingdom.View Verona Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Hims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity?Cirrus Logic Upgraded After Q3 Earnings Beat—More Gains Ahead? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
